| Vasculitis |
1 |
1 |
| Otolaryngology |
0 |
0.56 |
| Remission |
0 |
0.55 |
| Asthma |
0 |
0.46 |
| Biologic Therapy |
0 |
0.46 |
| Healthcare and Medical Technology |
0 |
0.46 |
| Clinical Research |
0 |
0.41 |
| Corticosteroids |
0 |
0.41 |
| Churg-Strauss Syndrome |
0 |
0.23 |
| Chronic Obstructive Pulmonary Disease |
0 |
0.15 |
| Headache |
0 |
0.15 |
| Nasal Polyp |
0 |
0.15 |
| Patient Safety |
0 |
0.15 |
| Adverse Effects |
0 |
0.14 |
| Child |
0 |
0.14 |
| Colorado |
0 |
0.14 |
| Eosinophils |
0 |
0.14 |
| Food and Drug Administration (FDA) |
0 |
0.14 |
| Glucocorticoid |
0 |
0.14 |
| Granulomatosis |
0 |
0.14 |
| Hypereosinophilic Syndrome |
0 |
0.14 |
| Interleukin |
0 |
0.14 |
| Monoclonal Antibody |
0 |
0.14 |
| Pharyngitis |
0 |
0.14 |
| Polyp |
0 |
0.14 |
| Quality of Life |
0 |
0.14 |
| Rare Diseases |
0 |
0.14 |
| Receptors |
0 |
0.14 |
| Refractory |
0 |
0.14 |
| Rhinosinusitis |
0 |
0.14 |
| Steroids |
0 |
0.14 |